Author: Ravi Shankar

Acquisition adds battery-free smart wound dressing and two-minute multi-marker screening test to Davion’s growing healthcare portfolio

DUBLIN, Oct. 26, 2026 (GLOBE NEWSWIRE) — Davion Healthcare Plc (Nasdaq: DAVI) (“Davion” or the “Company”), a next-generation digital healthcare company developing proprietary health monitoring technologies, today announces that it has completed the acquisition of the intellectual property relating to two medical technologies: WoundSkan, a smart wound-monitoring dressing, and the Spektra Lateral Flow Test, a rapid multi-marker screening platform.

The intellectual property was acquired from the four shareholders of Humaskan Ltd for a total consideration of US$25 million, comprising US$2.5 million in cash and 1,730,770 new ordinary shares in Davion, to be issued at an agreed fixed contractual value of US$13.00 per share (approximately US$22.5 million). The number of shares is fixed and will not vary with movements in the Davion’s share price.

The acquired technologies

WoundSkan is a smart wound dressing containing a temperature sensor and a passive NFC tag. It has no battery or internal power: scanning the dressing with a smartphone powers the sensor and sends the reading to the WoundSkan app. The app records each timestamped temperature reading alongside a reading history and patient notes, so clinicians can track wound temperature, a potential early sign of infection, without removing the dressing.

The Spektra Lateral Flow Test is a single-use screening platform. A onetime use base unit collects urine and saliva samples and takes one of ten colour-coded cartridges, each carrying antibodies for specific markers. Results are available in around two minutes and are sent to a smartphone by passive NFC.

The current cartridge range covers markers associated with certain cancers, hormonal imbalances, autoimmune conditions and neurodegenerative conditions. Although Spektra is not a diagnostic test, it is designed to identify anomalies that may warrant further clinical investigation.

Both technologies use the battery-free, smartphone-read approach that underpins Davion’s focus on health monitoring outside traditional clinical settings.

The acquisition includes the associated patents and patent applications, technical designs, software and algorithms, research and development data, testing information, regulatory documentation, prototypes and know-how. It also includes the rights to develop, manufacture, commercialise and license products incorporating the acquired intellectual property.

The transaction covers the intellectual property and associated assets only. Davion has not acquired Humaskan Ltd as a corporate entity, nor has it taken on its employees or assumed any of its liabilities.

Transaction terms

The consideration shares will be issued after a 90-day deferral period from listing, which will be on the 20^th January 2027. For the following 90 days thereafter, each Seller may sell no more than 10% of Davion’s five-day average daily trading volume on any trading day. The cash consideration is payable by 19 February 2027, within 120 days of the start of trading of Davion’s shares on Nasdaq.  

Strategy

The acquisition is Davion’s first since its direct listing on the Nasdaq Global Market on 22 October 2026. It follows the Group’s adoption of a direct commercialisation strategy in June 2026. Davion’s growth strategy combines the commercialisation of its proprietary technologies, including BreastCheck, with acquisitions across medical devices, healthcare services, medical distribution, healthcare technology and diagnostics.

To support its acquisition programme, Davion has established Davion Healthcare Finance Ltd and launched a £30 million five-year senior secured bond. The Group’s acquisition programme is overseen by its Operational Directorate, led by Chief Executive Officer Glenn Williams.

Glenn Williams, Chief Executive Officer of Davion Healthcare, commented:

“This acquisition is an important step in our plans to build a substantial international healthcare business, combining the development of our existing portfolio with the acquisition of complementary technologies.

“WoundSkan and Spektra are both innovative, practical technologies with considerable commercial potential. WoundSkan builds on our existing expertise in temperature-based monitoring, offering a way to assess wounds without removing dressings, while Spektra provides rapid screening for multiple conditions from a single sample. Both have applications across a range of healthcare settings.

“Following our recent Nasdaq listing, we are well positioned to accelerate the development and commercialisation of these technologies, while continuing to pursue further acquisition opportunities.”

Media Enquiries

Rosewood Communications
+44 (0) 20 7653 8702
davion@rosewoodpr.co.uk

Investor Relations Inquiries

Mark Komonoski
Partner
Integrous Communications
Toll Free: 877-255-8483
Mobile: 403-470-8384

About Davion Healthcare Plc

Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments.

The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion’s broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare.

Davion’s growth strategy combines the development and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group’s product portfolio and commercial, manufacturing and distribution capabilities.

Further information is available at www.davionhealthcare.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions.

The statements in this release are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements.

Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, the Company’s ability to license and protect its intellectual property, its ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against the Company, any governmental review of its products or practices, and other risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

The Company undertakes no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time, except as required by applicable law.

The investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.

26 October 2026

Notification no. 87/2026

Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation.

For further details, please find the attached template for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Contact: Stefan Kailay Wind, Nordic Head of Media Relations, tel. +45 45 14 14 00

Attachment

• APMH Invest AS – sale – 2026 10 23

WILMINGTON, DELAWARE, Oct. 26, 2026 (GLOBE NEWSWIRE) — CID HoldCo, Inc., doing business as Dot Ai (Nasdaq: DAIC) (“Dot Ai” or the “Company”), today announced the appointment of Avi Cohen to its Board of Directors. Cohen brings extensive experience leading technology companies through acquisitions, integration and expansion as Dot Ai enters its next phase of growth following the recent $65 million acquisition of its wholly owned subsidiary, Envoy Technologies.

As CEO of RR Media, Cohen oversaw a period of growth that included record annual revenue of $140.3 million in 2015, followed by the company’s acquisition by SES S.A. in 2016 in a transaction valued at $242 million. He subsequently became CEO of MX1, the business formed through the combination of RR Media and SES Platform Services. His earlier career includes executive leadership positions at Orbit Technologies, KLA Corporation and ECI Telecom.

Cohen’s board experience spans semiconductor technology, investigative analytics and corporate investment strategy, with roles at Nasdaq-listed Nova (NVMI), Cognyte Software (CGNT) and ZOOZ Strategy (ZOOZ). His involvement across these businesses brings a perspective shaped by different technology markets and business models.

“Avi brings experience that is particularly relevant to where we are today,” said Shmulik Yannay, CEO of Envoy Technologies. “He’s led a company through a significant acquisition and gone on to run the combined business. As Envoy enters this next chapter under Dot Ai, that firsthand understanding of how to bring businesses together and build on their strengths is extremely valuable.”

“Dot Ai has an opportunity to build on Envoy’s established business, its property relationships and the technology supporting its operations,” said Avi Cohen. “I see potential to expand that foundation while exploring opportunities across Dot Ai’s broader technology portfolio. I’m looking forward to working with the Board and management team to help turn those opportunities into sustainable growth.”

Dot Ai (Nasdaq: DAIC) completed its approximately $65 million all-stock acquisition of Envoy Technologies in October 2026. Envoy provides on-site electric vehicle car-sharing services to residential communities, hotels and resorts across the United States. 

About Envoy Technologies

Envoy provides on-site electric vehicle car-sharing services for residential communities, hotels, resorts and campus properties. Through the Envoy app, residents and guests can reserve shared electric vehicles by the hour or day, while Envoy manages insurance, maintenance and day-to-day operations. The service gives residents convenient access to electric transportation without the costs of individual vehicle ownership and offers property owners an additional amenity without the responsibility of managing vehicles.

Headquartered in Culver City, California, Envoy is a wholly owned subsidiary of Dot Ai (Nasdaq: DAIC).

For more information, visit https://www.envoythere.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, including statements regarding the anticipated benefits of the acquisition of Envoy, including, for example, the expected expansion of the Company’s commercial operations and market presence; opportunities to introduce and integrate Dot Ai’s asset-intelligence technology into Envoy’s existing platform and operations; the potential expansion of Envoy’s electric vehicle carsharing business into additional residential, hospitality, campus and international markets; anticipated revenue opportunities and future growth; the Company’s ability to successfully integrate Envoy’s business and operations; the Company’s belief regarding its stockholders’ equity and its ability to regain and maintain compliance with applicable Nasdaq listing requirements; the Company’s ability to obtain the required stockholder approval in connection with the transaction and the anticipated conversions of the Series C preferred stock and Envoy convertible note; and the Company’s ability to support Envoy’s operations and expansion. All forward-looking statements are based on Dot Ai’s current expectations and beliefs concerning future developments and their potential effects on the Company. Forward-looking statements are subject to risks and uncertainties — including the risk that required stockholder, Nasdaq, or regulatory approvals may not be obtained, that Nasdaq may not accept the Company’s evidence of compliance with the stockholders’ equity requirement, that the Company may not successfully integrate Envoy’s operations, that anticipated benefits and synergies of the acquisition may not be realized, that additional financing may not be available on acceptable terms or at all, and that the Company may be unable to regain or maintain compliance with applicable Nasdaq listing requirements — that could cause actual results to differ materially from those expressed in the forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and Dot Ai assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Important Information for Stockholders

In connection with the proposed transactions, the Company intends to file a proxy statement with the SEC. The Company also plans to file other documents with the SEC regarding the proposed transactions. After the proxy statement has been cleared by the SEC, a definitive proxy statement will be filed with the SEC and mailed to the stockholders of record of the Company. The Board will set the record date prior to mailing the definitive proxy statement. STOCKHOLDERS OF THE COMPANY ARE URGED TO CAREFULLY READ THE PROXY STATEMENT (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE PROPOSED TRANSACTIONS THAT WILL BE FILED WITH THE SEC IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS. Stockholders will be able to obtain free copies of the proxy statement and other documents containing important information about the Company once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov.

Participants in the Solicitation

The Company and its executive officers, directors, other members of management and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Company’s stockholders with respect to the proposed transactions. Information regarding the executive officers and directors of the Company is set forth in the Company’s definitive proxy statement for the Company’s 2026 annual meeting of stockholders filed with the SEC on April 17, 2026 and in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 11, 2026. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the transactions contemplated by the Purchase Agreement.

No Offer or Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transactions and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

# # #

Contact:
DAIC
Charles Maddox, CFO
Investors@daic.ai

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Gamma Communications plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	23/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.25p ordinary
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	761,936	0.85
(2)   Cash-settled derivatives:	471,621	0.52
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,233,557	1.38

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.25p ordinary	Equity swap	Reducing a long position	16,162	10.9103 GBP

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	26/10/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

• Single agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of 25% and a DCR of 44%
• Safety profile was manageable; further dose optimization being pursued with lower dose of 3 mg/kg Q3W
• Anticipate sharing updated LINNET results in first half of 2027

ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. 

“Clear cell gynecologic malignancies are notoriously aggressive, resistant to conventional platinum-based chemotherapies, and carry a poor prognosis. New targeted treatments are urgently needed,” said Amir Jazaeri, M.D., Professor and Vice Chair for Clinical Research in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, and lead author of the poster. “The 25% response rate and manageable tolerability profile in CCGC observed in the LINNET study represent a highly encouraging potential therapeutic signal for a single agent in this difficult-to-treat histological subtype.”

Encouraging Activity and Manageable Safety Profile

As of the data cutoff of September 1, 2026, 41 patients with advanced gynecologic cancers, including high-grade serous epithelial platinum-resistant ovarian cancer (PROC) (n=24) and CCGC (n=17), including ovarian, endometrial, vaginal, vulval, or cervical cancer, had been treated with lorigerlimab administered intravenously every three weeks (Q3W) at 6 mg/kg. The PROC study participants had received a median of two prior lines of therapy (range 1-3) and the CCGC patients had received a median of one prior line of therapy (range 1-3).

All 41 patients were evaluable for safety. In these patients, lorigerlimab demonstrated a manageable safety profile that was consistent with dual PD-1/CTLA-4 blockade. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 49% of patients, with the most common events (observed in ≥5% of participants) being anemia (10%), neutrophil count decreased (10%) and aspartate aminotransferase increased (7%). There was one Grade 5 TRAE in the PROC Cohort. TRAEs led to discontinuation of lorigerlimab in 24% of all patients (18% in CCGC patients).

Among 16 response-evaluable patients with CCGC, the confirmed objective response rate (ORR) was 25% (4/16), and the disease control rate was 44% (7/16). All responses remained ongoing at data cutoff. In the 17 safety-evaluable patients with CCGC, the median progression-free survival (PFS) was 2.9 months (95% CI, 1.9-6.2) and PFS rate at 6 months was 33%.

MacroGenics is enrolling 20 additional CCGC patients at a dose of 3 mg/kg Q3W and the Company anticipates reporting updated study results in the first half of 2027.

“We are encouraged by the efficacy and manageable safety profile demonstrated in the Phase 2 LINNET study to date and these results mark an important milestone for lorigerlimab and highlight its potential for treating patients facing clear cell gynecologic cancers,” said Eric Risser, President and Chief Executive Officer of MacroGenics. “We believe these data support the promise of dual PD-1/CTLA-4 blockade and lorigerlimab’s potential to improve the treatment paradigm for this underserved patient population.”

Poster Presentation Details

Title: LINNET: A Phase 2 Study to Evaluate Lorigerlimab in Participants With Advanced Gynecologic Cancers
Lead author: Amir A. Jazaeri, M.D.
Session: Gynaecological Cancers
Poster number: 1278P
Date and time: Monday, October 26, 2026, from 12:00 to 12:45 PM CEST

A copy of the above ESMO poster presentation is available on the Company’s Investor Relations website through this direct link: ESMO poster presentation.

About the Phase 2 LINNET Study

The Phase 2 LINNET study was designed to evaluate single-agent lorigerlimab in PROC and CCGC patients who had received one or more prior lines of systemic therapy. The study’s primary endpoint is ORR, with multiple secondary endpoints. As of the September 1, 2026 data cutoff, 42 study participants had been dosed in this study, and more than 300 study participants had been dosed across all previous lorigerlimab Phase 1 and Phase 2 clinical trials. Additional information about the study is available at www.clinicaltrials.gov using the identifier NCT06730347.

About Lorigerlimab

Lorigerlimab (previously known as MGD019) is an investigational, tetravalent bispecific IgG4-based, Fc-bearing DART molecule that was designed to enhance blockade on PD-1 and CTLA-4 dual-expressing, tumor-infiltrating lymphocytes, while maintaining maximal PD-1 blockade on all circulating PD-1-expressing cells.

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART® are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of clinical updates and safety and efficacy data for the Company’s ongoing clinical trials, anticipated cash runway and other statements containing the words “subject to”, “believe”, “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy, including our ability to execute on our key strategic priorities for 2026, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks related to the reproducibility of any results initially seen in any product candidate including the results for lorigerlimab discussed herein; risks that any product candidate’s revenue, expenses and costs may not be as expected; risks relating to any other product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data updates for lorigerlimab any other product candidates, including timing and results of efficacy and safety data with respect to lorigerlimab any other product candidates in ongoing clinical trials; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations regarding the expansion of ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company’s product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; risks related to the transition of the CDMO operations to the purchaser following the sale of our CDMO operations; and other risks described in the Company’s filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

CONTACT: CONTACTS
Jim Karrels, Senior Vice President, CFO
1-301-251-5172
info@macrogenics.com

Argot Partners
1-212-600-1902
macrogenics@argotpartners.com

Initiative Builds on First Commercial Yarn Shipment to Create New Constructions and Blends for the Next Generation of Fabrics and Apparel

ANN ARBOR, Mich., Oct. 26, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced the launch of a new program to develop innovative performance yarns built on its recombinant spider silk. The Company also announced that it has shipped samples of its spider silk to an innovative firm with a history of collaborating with tier-1 aerospace manufacturers to develop new materials. The yarn development program builds directly on the Company’s recent sale and shipment of a custom yarn to a performance apparel customer.

The program has a clear purpose; Kraig Labs will develop new yarn constructions and new material blends. These yarns will be designed from the ground up to enable new fabrics, new apparel, and new materials. Each one will leverage the performance and the rarity of spider silk.

Kraig Labs’ first custom yarn proved the process and opened the door to a broader effort and opportunities to bring innovation in materials performance from the lab to the market.

“Our first custom yarn showed that it is now possible to produce and deliver spider silk to industry,” said Kim Thompson, Founder and CEO of Kraig Labs. “This program takes that further. We are launching the development of new yarns, new constructions, and new blends. Each one is built around the performance and capabilities of spider silk.”

The Company expects the program to serve as the groundwork for multiple commercialization paths, potentially including new collaborations with brands, mills, and manufacturers, to Kraig Labs’ own innovation in apparel.

This initial shipment was sent out at the request of this innovator in textiles. The recipient is known for developing some of the world’s most advanced yarn spinning equipment. Their expertise and leadership in this space has earned their place in collaboration alongside tier-1 aerospace manufacturers to develop next gen fibers and hybrid structures. Their work is centered where strength, weight, and performance decide outcomes. This shipment puts recombinant spider silk in front of a team with deep experience in demanding applications.

“Spider silk is a material that will earn its place through performance,” Thompson said. “Sending samples of our silk to a firm with this background puts it in front of people who know exactly how to leverage materials with exceptional performance. Every great fabric starts with a yarn. This program is where we build that foundation.”

The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering.

You can see Kraig Labs featured in Veritasium’s spider silk video at https://www.youtube.com/watch?v=wt4p2oalmRY.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Third Quarter Highlights

• Net income of $31.4 million, or $0.86 per diluted share; return on average assets (“ROAA”) of 1.85%; return on average stockholders’ equity (“ROAE”) of 16.17%; and return on average tangible common equity (“ROATCE”)⁽¹⁾ of 19.27%
• Adjusted net income⁽¹⁾ of $31.4 million, or $0.86 per diluted share; adjusted ROAA⁽¹⁾ of 1.85%; adjusted ROAE⁽¹⁾ of 16.18%; and adjusted ROATCE⁽¹⁾ of 19.29%
• Asset quality remains strong, with nonperforming assets to total assets of 0.16% and net recoveries to average loans of 0.04%, on an annualized basis
• Net interest margin increased 3 basis points to 4.35%, and net interest margin (tax-equivalent basis)⁽¹⁾ increased 2 basis points to 4.40%

BLOOMINGTON Ill., Oct. 26, 2026 (GLOBE NEWSWIRE) — HBT Financial, Inc. (NASDAQ: HBT) (the “Company”, “HBT Financial” or “HBT”), the holding company for Heartland Bank and Trust Company, today reported net income of $31.4 million, or $0.86 diluted earnings per share, for the third quarter of 2026. This compares to net income of $27.8 million, or $0.76 diluted earnings per share, for the second quarter of 2026, and net income of $19.8 million, or $0.63 diluted earnings per share, for the third quarter of 2025.

J. Lance Carter, President and Chief Executive Officer of HBT Financial, said, “Our third quarter results were very strong with adjusted net income⁽¹⁾ of $31.4 million, or $0.86 per diluted share, an increase of 10.1% over the prior quarter. Profitability also remained strong with adjusted ROAA⁽¹⁾ of 1.85% and adjusted ROATCE⁽¹⁾ of 19.29%. Our net interest margin on a tax equivalent basis⁽¹⁾ was 4.40%, an increase of 2 basis points compared to the second quarter of 2026, as maturing fixed-rate loans repriced higher and securities cash flows were reinvested at higher rates, slightly offset by a higher cost of funds and lower loan accretion income. Noninterest income was above expectations, aided by wealth management, seasonally higher mortgage income, and a nonrecurring $0.4 million excise tax refund. Expenses were well controlled during the quarter, with an efficiency ratio on a tax equivalent basis⁽¹⁾ of 48.24%. Asset quality also remains exceptional, with nonperforming assets to total assets of 0.16%, and net recoveries to average loans of 0.04%, on an annualized basis, during the quarter. Finally, our balance sheet remains strong with all regulatory capital ratios increasing during the quarter, including a common equity tier 1 capital ratio of 12.94% and total capital to risk-weighted assets ratio of 16.48%.

Integration planning for the acquisition of Tri-County Financial Group, Inc. is progressing well, and we anticipate this transaction closing early in the first quarter of 2027, subject to their stockholder approval and regulatory approvals. We have been very impressed with their people and overall organization, and we are looking forward to a successful closing.”
____________________________________
(1)   See “Reconciliation of Non-GAAP Financial Measures” below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.

Adjusted Net Income

In addition to reporting GAAP results, the Company believes non-GAAP measures such as adjusted net income and adjusted earnings per share, which adjust for acquisition expenses, branch closure expenses, net earnings (losses) on closed or sold operations, losses on extinguishment of debt, gains (losses) on closed branch premises, realized gains (losses) on sales of securities, mortgage servicing rights (“MSR”) fair value adjustments, and the tax effect of these pre-tax adjustments, provide investors with additional insight into its operational performance. The Company reported adjusted net income of $31.4 million, or $0.86 adjusted diluted earnings per share, for the third quarter of 2026. This compares to adjusted net income of $28.5 million, or $0.78 adjusted diluted earnings per share, for the second quarter of 2026, and adjusted net income of $20.5 million, or $0.65 adjusted diluted earnings per share, for the third quarter of 2025. See “Reconciliation of Non-GAAP Financial Measures” tables below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.

Pending Acquisition of Tri-County Financial Group, Inc. and Completed Transaction with CNB Bank Shares, Inc.

On August 10, 2026, HBT Financial and Tri-County Financial Group, Inc. (“TYFG” or “Tri-County”), the holding company for First State Bank (“FSB”), jointly announced the signing of a definitive agreement pursuant to which HBT Financial will acquire TYFG and FSB. The acquisition will increase HBT Financial’s density in its central Illinois and Chicago MSA markets. The transaction is expected to close early in the first quarter of 2027, subject to their stockholder approval and regulatory approvals.

CNB Bank Shares, Inc. (“CNB”) and TYFG acquisition-related expenses during the second and third quarter of 2026 and during the nine months ended September 30, 2026 are summarized below. There were no acquisition-related expenses during the third quarter of 2025 or during the nine months ended September 30, 2025.

	Three Months Ended												Nine Months Ended
(dollars in thousands)	September 30, 2026				June 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
Salaries	$	58			$	(44	)		$	—			$	4,017			$	—
Occupancy of bank premises		—				13				—				118				—
Furniture and equipment		—				9				—				72				—
Data processing		260				91				—				9,019				—
Marketing and customer relations		—				5				—				74				—
Loan collection and servicing		—				28				—				348				—
Professional fees and other noninterest expense		687				155				—				3,280				—
Total acquisition-related expenses	$	1,005			$	257			$	—			$	16,928			$	—

Net Interest Income and Net Interest Margin

Net interest income for the third quarter of 2026 was $70.3 million, an increase of 1.8% from $69.1 million for the second quarter of 2026. The increase was primarily attributable to higher yields on loans and higher average loan balances. A $0.5 million increase in loan fees and a $0.2 million increase in nonaccrual interest recoveries further contributed to the overall increase. Partially offsetting these increases were an $0.8 million decrease in acquired loan discount accretion, which totaled $1.3 million for the third quarter of 2026, and higher funding costs.

Relative to the third quarter of 2025, net interest income increased 40.7% from $50.0 million. The increase was primarily attributable to higher average interest-earning asset balances following the CNB merger and improved yields on debt securities and loans. Additionally, a $0.4 million increase in acquired loan discount accretion, a $0.4 million increase in loan fees, and a $0.3 million increase in nonaccrual interest recoveries further contributed to the improvement.

Net interest margin for the third quarter of 2026 was 4.35%, compared to 4.32% for the second quarter of 2026, while net interest margin (tax-equivalent basis)⁽¹⁾ for the third quarter of 2026 was 4.40%, compared to 4.38% for the second quarter of 2026. These increases were primarily attributable to improved yields on loans, which increased 5 basis points to 6.43%. These increases were partially offset by higher funding costs, which increased 4 basis points to 1.36%, driven primarily by increases in benchmark interest rates.

Relative to the third quarter of 2025, net interest margin increased 22 basis points from 4.13% and net interest margin (tax-equivalent basis)⁽¹⁾ increased 22 basis points from 4.18%. These increases were primarily attributable to improved yields on debt securities and loans as well as a more favorable interest-earning asset mix, which were partially offset by higher funding costs.
____________________________________
(1)   See “Reconciliation of Non-GAAP Financial Measures” below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.

Noninterest Income

Noninterest income for the third quarter of 2026 was $14.2 million, a 20.2% increase from $11.8 million for the second quarter of 2026. The increase was primarily attributable to changes in the MSR fair value adjustment, with a $1.5 million positive MSR fair value adjustment included in the third quarter of 2026 results compared to an $0.8 million negative MSR fair value adjustment included in the second quarter of 2026 results. Additionally, a $0.4 million nonrecurring refund of stock repurchase excise tax as a result of a change in tax regulation included in other noninterest income contributed to the improvement.

Relative to the third quarter of 2025, noninterest income increased 44.6% from $9.8 million. The increase was primarily attributable to changes in the MSR fair value adjustment, with a $1.5 million positive MSR fair value adjustment included in the third quarter of 2026 results compared to a $0.5 million negative MSR fair value adjustment included in the third quarter of 2025 results. Additionally, an $0.8 million increase in wealth management fees, a $0.6 million increase in service charges on deposit accounts, and a $0.5 million increase in card income, all primarily driven by a larger customer base following the CNB merger, contributed to the increase.

Noninterest Expense

Noninterest expense for the third quarter of 2026 was $42.7 million, a 0.5% increase from the second quarter of 2026. Acquisition-related noninterest expenses totaled $1.0 million during the third quarter of 2026, compared to $0.3 million during the second quarter of 2026. Excluding acquisition-related expenses, noninterest expense for the third quarter of 2026 was $41.7 million, a $0.5 million decrease from the second quarter of 2026. The decrease was primarily attributable to a $1.1 million decrease in salaries expense, which was partially offset by a $0.4 million increase in occupancy expense, primarily due to planned building maintenance and upgrades, and a $0.3 million increase in employee benefits expense, driven by higher medical benefits costs.

Relative to the third quarter of 2025, noninterest expense increased 31.2% from $32.5 million. Excluding acquisition-related expenses, the $9.2 million increase in noninterest expense was primarily attributable to higher base costs following the CNB merger, including a $5.8 million increase in salaries and employee benefits expenses, which were also driven higher by annual merit increases and higher medical benefits costs, as well as increases in occupancy, data processing, and marketing expenses.

Loan Portfolio

Total loans outstanding, before allowance for credit losses, were $4.78 billion at September 30, 2026, compared with $4.75 billion at June 30, 2026, and $3.40 billion at September 30, 2025. The $30.3 million increase from June 30, 2026 was primarily due to new fundings and draws on existing loans within the construction and land development category, partially offset by seasonal reductions of $8.8 million on grain elevator lines within the commercial and industrial category, as well as several payoffs due to refinance within the multifamily category.

Deposits

Total deposits were $5.75 billion at September 30, 2026, compared with $5.76 billion at June 30, 2026, and $4.35 billion at September 30, 2025. The $5.6 million decrease from June 30, 2026 was primarily attributable to lower balances maintained in existing retail accounts and seasonally lower public funds balances, which were partially offset by an increase in business account balances. Additionally, $60.0 million of wealth management customer reciprocal deposits were moved on-balance sheet during the third quarter of 2026.

Asset Quality

Nonperforming assets totaled $10.8 million, or 0.16% of total assets, at September 30, 2026, compared with $9.9 million, or 0.15% of total assets, at June 30, 2026, and $8.6 million, or 0.17% of total assets, at September 30, 2025. The majority of the $0.9 million increase in nonperforming assets from June 30, 2026 was attributable to increases in nonaccrual loan balances in the one-to-four family residential category. Additionally, of the $10.1 million of nonperforming loans held as of September 30, 2026, $2.4 million were either wholly or partially guaranteed by the U.S. government.

The Company recorded a negative provision for credit losses of $0.6 million for the third quarter of 2026. The negative provision for credit losses primarily reflects a $1.9 million decrease in required reserves driven by changes within the portfolio, which included net recoveries of $0.5 million; a $0.6 million decrease in required reserves driven by changes in the economic forecast; a $0.1 million decrease in specific reserves; and a $2.0 million increase in required reserves resulting from changes in qualitative factors.

The Company had net recoveries of $0.5 million, or 0.04% of average loans on an annualized basis, for the third quarter of 2026, compared to net recoveries of $0.1 million, or 0.01% of average loans on an annualized basis, for the second quarter of 2026, and net charge-offs of $0.1 million, or 0.02% of average loans on an annualized basis, for the third quarter of 2025.

The Company’s allowance for credit losses was 1.26% of total loans and 599% of nonperforming loans at September 30, 2026, compared with 1.27% of total loans and 666% of nonperforming loans at June 30, 2026. In addition, the allowance for credit losses on unfunded lending-related commitments totaled $6.6 million as of September 30, 2026, compared with $6.6 million as of June 30, 2026.

Capital

As of September 30, 2026, the Company exceeded all regulatory capital requirements under Basel III as summarized in the following table:

		September 30, 2026				For Capital Adequacy Purposes With Capital Conservation Buffer
Total capital to risk-weighted assets		16.48	%			10.50	%
Tier 1 capital to risk-weighted assets		13.88				8.50
Common equity tier 1 capital ratio		12.94				7.00
Tier 1 leverage ratio		11.33				4.00

The ratio of tangible common equity to tangible assets⁽¹⁾ decreased to 9.56% as of September 30, 2026, from 9.69% as of June 30, 2026, and tangible book value per share⁽¹⁾ decreased by $0.26 to $17.34 as of September 30, 2026, when compared to June 30, 2026. The decrease in tangible book value per share was primarily driven by a decrease in accumulated other comprehensive income as a result of higher net unrealized losses on available-for-sale debt securities as market interest rates increased during the quarter.

During the third quarter of 2026, the Company did not repurchase shares of its common stock under its stock repurchase program. The Company is currently subject to a blackout period restricting repurchases of its common stock, which will remain in effect until the conclusion of the TYFG stockholder vote on the proposed merger scheduled for October 29, 2026. The Company’s Board of Directors has authorized the repurchase of up to $30.0 million of HBT Financial common stock under its stock repurchase program, which is in effect until January 1, 2027. As of September 30, 2026, the Company had $14.0 million remaining under the stock repurchase program.
____________________________________
(1)   See “Reconciliation of Non-GAAP Financial Measures” below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.

About HBT Financial, Inc.

HBT Financial, Inc., headquartered in Bloomington, Illinois, is the holding company for Heartland Bank and Trust Company, and has banking roots that can be traced back to 1920. HBT Financial provides a comprehensive suite of financial products and services to consumers, businesses, and municipal entities throughout Illinois, eastern Iowa, and suburban St. Louis through 83 full-service branches. As of September 30, 2026, HBT Financial had total assets of $6.7 billion, total loans of $4.8 billion, and total deposits of $5.8 billion.

Non-GAAP Financial Measures

Some of the financial measures included in this press release are not measures of financial performance recognized in accordance with GAAP. These non-GAAP financial measures include adjusted net income, adjusted earnings per share, adjusted ROAA, pre-provision net revenue, pre-provision net revenue less charge-offs (recoveries), adjusted pre-provision net revenue, adjusted pre-provision net revenue less charge-offs (recoveries), net interest income (tax-equivalent basis), net interest margin (tax-equivalent basis), efficiency ratio (tax-equivalent basis), adjusted efficiency ratio (tax-equivalent basis), the ratio of tangible common equity to tangible assets, tangible book value per share, adjusted ROAE, ROATCE, and adjusted ROATCE. Our management uses these non-GAAP financial measures, together with the related GAAP financial measures, in its analysis of our performance and in making business decisions. Management believes that it is a standard practice in the banking industry to present these non-GAAP financial measures, and accordingly believes that providing these measures may be useful for peer comparison purposes. These disclosures should not be viewed as substitutes for the results determined to be in accordance with GAAP; nor are they necessarily comparable to non-GAAP financial measures that may be presented by other companies. See our reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures in the “Reconciliation of Non-GAAP Financial Measures” tables.

Forward-Looking Statements

Readers should note that in addition to the historical information contained herein, this press release contains, and future oral and written statements of the Company and its management may contain, “forward-looking statements” within the meanings of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “will,” “propose,” “may,” “plan,” “seek,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “continue,” or “should,” or similar terminology and the negative forms of such words. Any forward-looking statements presented herein are made only as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking statements to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

Factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to: (1) the strength of the local, state, national and international economies and financial markets (including effects of inflationary pressures, global energy market conditions, the threat or implementation of tariffs, immigration enforcement and changes in foreign policy); (2) policy changes in, and the interpretation and prioritization of, local, state and federal laws, regulations and governmental policies, including executive orders; (3) the economic impact of any future terrorist threats and attacks, widespread disease or pandemics, acts of war or other threats thereof (including the Russian invasion of Ukraine, ongoing conflicts in the Middle East, and other international military conflicts that can increase levels of political and economic unpredictability, contribute to rising energy and commodity prices, affect global supply chains, increase the volatility of financial markets, and other matters beyond our control), and the response of the local, state and national governments to any such adverse external events; (4) new and revised accounting policies and practices, as may be adopted by state and federal regulatory banking agencies, the Financial Accounting Standards Board or the Public Company Accounting Oversight Board; (5) the imposition of tariffs or other governmental policies impacting the value of products produced by the Company’s commercial borrowers; (6) changes in interest rates, including as a result of the recent increase in the benchmark federal funds rate by the Federal Reserve, and prepayment rates of the Company’s assets; (7) increased competition in the financial services sector, including from non-bank competitors such as credit unions, private credit firms, fintech companies, and digital asset service providers, and the inability to attract new customers; (8) technological changes implemented by us and other parties, including our third-party vendors, which may have unforeseen consequences to us and our customers; (9) emerging issues related to the development and use of artificial intelligence that could give rise to legal or regulatory action, damage our reputation or otherwise materially harm our business or customers; (10) unexpected results of acquisitions, which may include failure to realize the anticipated benefits of acquisitions and the possibility that transaction costs may be greater than anticipated, including the acquisition of CNB; (11) the loss of key executives and employees, talent shortages and employee turnover; (12) changes in consumer spending; (13) unexpected outcomes or costs of existing or new litigation or other legal proceedings and regulatory actions involving the Company; (14) the economic impact on the Company and its customers of climate change, natural disasters and of exceptional weather occurrences such as tornadoes, floods and blizzards; (15) fluctuations in the value of securities held in our securities portfolio, including as a result of changes in interest rates; (16) credit risks and risks from concentrations (by type of borrower, geographic area, collateral and industry) within our loan portfolio (including commercial real estate loans) and large loans to certain borrowers; (17) the overall health of the local and national real estate market; (18) the ability to maintain an adequate level of allowance for credit losses on loans; (19) the concentration of large deposits from certain clients who have balances above current FDIC insurance limits and who may withdraw deposits to diversify their exposure; (20) the availability of future equity and debt issuances and other capital raising opportunities on favorable terms; (21) the ability to successfully manage liquidity risk, which may increase dependence on non-core funding sources such as brokered deposits, and may negatively impact the Company’s cost of funds; (22) the level of nonperforming assets on our balance sheet; (23) interruptions involving our information technology and communications systems or those of our third-party servicers; (24) the occurrence of fraudulent activity, breaches or failures of our third-party vendors’ information security controls or cybersecurity-related incidents, including as a result of sophisticated attacks using artificial intelligence and similar tools or as a result of insider fraud; (25) the effectiveness of the Company’s risk management framework; (26) the possibility that stockholders of TYFG may not approve the merger agreement; (27) the risk that a condition to closing of the proposed transaction may not be satisfied, that either party may terminate the merger agreement or that the closing of the proposed transaction might be delayed or not occur at all; (28) potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction; (29) the diversion of management time on transaction-related issues; (30) the ultimate timing, outcome and results of integrating the operations of TYFG into those of HBT; (31) the effects of the merger in HBT’s future financial condition, results of operations, strategy and plans; (32) regulatory approvals of the transaction; and (33) the ability of the Company to manage the risks associated with the foregoing as well as anticipated.

Readers should note that the forward-looking statements included in this press release are not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking statements. Additional information concerning the Company and its business, including additional factors that could materially affect the Company’s financial results, is included in the Company’s filings with the Securities and Exchange Commission.

Important Information and Where to Find It

In connection with the proposed Tri-County transaction, HBT Financial has filed and will file materials with the SEC, including a Registration Statement on Form S-4 of HBT Financial that included a proxy statement of Tri-County and a prospectus of HBT Financial. The Registration Statement has been declared effective by the SEC, and on or about September 18, 2026, HBT Financial and Tri-County mailed a definitive proxy statement/prospectus to the stockholders of Tri-County in connection with its special meeting of stockholders to be held on October 29, 2026. This news release is not a substitute for the proxy statement/prospectus or the Registration Statement or for any other document that HBT Financial and Tri-County may file with the SEC and send to Tri-County’s stockholders in connection with the proposed transaction. TRI-COUNTY’S STOCKHOLDERS ARE URGED TO CAREFULLY AND THOROUGHLY READ THE PROXY STATEMENT/PROSPECTUS AND THE REGISTRATION STATEMENT, AS MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED BY HBT FINANCIAL AND TRI-COUNTY WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HBT FINANCIAL, TRI-COUNTY, THE PROPOSED TRANSACTION, THE RISKS RELATED THERETO AND RELATED MATTERS.

Investors may obtain free copies of the Registration Statement and the definitive proxy statement/prospectus, as each may be amended from time to time, and other relevant documents filed by HBT Financial and Tri-County with the SEC (when they become available), through the website maintained by the SEC at www.sec.gov. Copies of documents filed with the SEC by HBT Financial are available free of charge from HBT Financial’s website at https://ir.hbtfinancial.com or by contacting HBT Financial’s Investor Relations Department at HBTIR@hbtbank.com. Copies of documents filed with the SEC by Tri-County are not available on Tri-County’s website, but will be provided free of charge upon request. To request such documents, please call (815) 538-2265.

Participants in the Proxy Solicitation

HBT Financial, Tri-County and their respective directors and certain of their executive officers and other members of management and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from Tri-County’s stockholders in connection with the proposed transaction. Information regarding the executive officers and directors of HBT Financial is included in its definitive proxy statement for its 2026 annual meeting filed with the SEC on April 8, 2026. Information regarding the executive officers and directors of Tri-County and additional information regarding the persons who may be deemed participants and their direct and indirect interests, by security holdings or otherwise, is set forth in the Registration Statement and definitive proxy statement/prospectus filed, and other materials when they are filed, with the SEC in connection with the proposed transaction. Free copies of these documents may be obtained as described in the paragraphs above.

No Offer or Solicitation

Communications in this news release do not constitute an offer to sell or the solicitation of an offer to subscribe for or buy any securities or a solicitation of any vote or approval with respect to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

CONTACT:
Peter Chapman
HBTIR@hbtbank.com
(309) 664-4556

HBT Financial, Inc. Unaudited Consolidated Financial Summary
		As of or for the Three Months Ended												Nine Months Ended September 30,
(dollars in thousands, except per share data)		September 30, 2026				June 30, 2026				September 30, 2025					2026				2025
Interest and dividend income		$	90,662			$	88,583			$	64,336			$	251,084			$	191,393
Interest expense			20,341				19,527				14,350				55,320				43,041
Net interest income			70,321				69,056				49,986				195,764				148,352
Provision for credit losses			(561	)			676				596				(41	)			1,698
Net interest income after provision for credit losses			70,882				68,380				49,390				195,805				146,654
Noninterest income			14,237				11,841				9,849				37,022				28,295
Noninterest expense			42,663				42,446				32,508				137,546				96,357
Income before income tax expense			42,456				37,775				26,731				95,281				78,592
Income tax expense			11,064				9,931				6,966				24,845				20,522
Net income		$	31,392			$	27,844			$	19,765			$	70,436			$	58,070
Earnings per share – diluted		$	0.86			$	0.76			$	0.63			$	1.99			$	1.84
Adjusted net income(1)		$	31,411			$	28,535			$	20,452			$	82,556			$	59,508
Adjusted earnings per share – diluted(1)			0.86				0.78				0.65				2.33				1.88
Book value per share		$	20.74			$	21.03			$	19.05
Tangible book value per share(1)			17.34				17.60				16.64
Shares of common stock outstanding			36,365,612				36,365,612				31,455,803
Weighted average shares of common stock outstanding, including all dilutive potential shares			36,489,423				36,466,688				31,587,935				35,430,418				31,628,929
SUMMARY RATIOS
Net interest margin *			4.35	%			4.32	%			4.13	%			4.30	%			4.13	%
Net interest margin (tax-equivalent basis) *(1)(2)			4.40				4.38				4.18				4.35				4.18
Efficiency ratio			48.73	%			50.67	%			53.17	%			57.46	%			53.37	%
Efficiency ratio (tax-equivalent basis)(1)(2)			48.24				50.14				52.68				56.88				52.88
Loan to deposit ratio			83.14	%			82.54	%			78.21	%
Return on average assets *			1.85	%			1.66	%			1.56	%			1.47	%			1.54	%
Return on average stockholders’ equity *			16.17				14.73				13.31				12.84				13.57
Return on average tangible common equity *(1)			19.27				17.69				15.28				15.23				15.66
Adjusted return on average assets *(1)			1.85	%			1.70	%			1.61	%			1.73	%			1.58	%
Adjusted return on average stockholders’ equity *(1)			16.18				15.09				13.77				15.05				13.90
Adjusted return on average tangible common equity *(1)			19.29				18.13				15.81				17.85				16.05
CAPITAL
Total capital to risk-weighted assets			16.48	%			16.20	%			16.77	%
Tier 1 capital to risk-weighted assets			13.88				13.59				15.67
Common equity tier 1 capital ratio			12.94				12.64				14.35
Tier 1 leverage ratio			11.33				11.01				12.16
Total stockholders’ equity to total assets			11.22				11.37				11.90
Tangible common equity to tangible assets(1)			9.56				9.69				10.56
ASSET QUALITY
Net charge-offs (recoveries) to average loans *			(0.04)	%			(0.01)	%			0.02	%			0.00	%			0.06	%
Allowance for credit losses to loans, before allowance for credit losses			1.26				1.27				1.23
Nonperforming loans to loans, before allowance for credit losses			0.21				0.19				0.22
Nonperforming assets to total assets			0.16				0.15				0.17

____________________________________

*  Annualized measure.

(1)   See “Reconciliation of Non-GAAP Financial Measures” below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.
(2)   On a tax-equivalent basis assuming a federal income tax rate of 21% and a state income tax rate of 9.5%.

HBT Financial, Inc. Unaudited Consolidated Financial Summary Consolidated Statements of Income
	Three Months Ended												Nine Months Ended September 30,
(dollars in thousands, except per share data)	September 30, 2026				June 30, 2026				September 30, 2025					2026				2025
INTEREST AND DIVIDEND INCOME
Loans, including fees:
Taxable	$	75,894			$	73,668			$	52,818			$	208,443			$	159,343
Federally tax exempt		1,501				1,539				1,245				4,357				3,628
Debt securities:
Taxable		11,359				11,167				8,320				32,070				22,690
Federally tax exempt		1,045				1,001				459				2,704				1,385
Interest-bearing deposits in bank		735				1,024				1,350				3,035				3,959
Other interest and dividend income		128				184				144				475				388
Total interest and dividend income		90,662				88,583				64,336				251,084				191,393
INTEREST EXPENSE
Deposits		18,122				17,253				12,995				49,484				38,769
Securities sold under agreements to repurchase		—				14				—				30				22
Borrowings		126				170				31				505				170
Subordinated notes		1,233				1,245				387				2,756				1,326
Junior subordinated debentures issued to capital trusts		860				845				937				2,545				2,754
Total interest expense		20,341				19,527				14,350				55,320				43,041
Net interest income		70,321				69,056				49,986				195,764				148,352
PROVISION FOR CREDIT LOSSES		(561	)			676				596				(41	)			1,698
Net interest income after provision for credit losses		70,882				68,380				49,390				195,805				146,654
NONINTEREST INCOME
Card income		3,247				3,428				2,732				9,426				8,077
Wealth management fees		3,943				3,917				3,122				11,624				8,789
Service charges on deposit accounts		2,680				2,489				2,093				7,329				5,952
Mortgage servicing		1,111				1,143				1,019				3,237				3,051
Mortgage servicing rights fair value adjustment		1,460				(751	)			(514	)			906				(1,573	)
Gains on sale of mortgage loans		550				412				390				1,293				1,101
Realized gains (losses) on sales of securities		(184	)			—				(49	)			(184	)			(49	)
Unrealized gains (losses) on equity securities		(71	)			191				(67	)			8				(36	)
Gains (losses) on foreclosed assets		(67	)			(129	)			148				(156	)			175
Gains (losses) on other assets		(62	)			(2	)			(14	)			(274	)			(88	)
Income on bank owned life insurance		229				206				169				623				500
Other noninterest income		1,401				937				820				3,190				2,396
Total noninterest income		14,237				11,841				9,849				37,022				28,295
NONINTEREST EXPENSE
Salaries		20,988				21,981				16,351				66,030				49,856
Employee benefits		4,493				4,185				3,314				12,598				10,179
Occupancy of bank premises		3,933				3,509				2,826				10,566				7,922
Furniture and equipment		861				931				737				2,400				1,757
Data processing		4,130				3,763				2,791				19,687				8,195
Marketing and customer relations		1,222				1,386				1,035				3,752				3,199
Amortization of intangible assets		1,455				1,455				694				3,797				2,083
Loss on extinguishment of debt		—				—				391				—				391
FDIC insurance		723				677				561				1,988				1,674
Loan collection and servicing		640				555				264				1,891				1,007
Foreclosed assets		43				40				62				143				134
Other noninterest expense		4,175				3,964				3,482				14,694				9,960
Total noninterest expense		42,663				42,446				32,508				137,546				96,357
INCOME BEFORE INCOME TAX EXPENSE		42,456				37,775				26,731				95,281				78,592
INCOME TAX EXPENSE		11,064				9,931				6,966				24,845				20,522
NET INCOME	$	31,392			$	27,844			$	19,765			$	70,436			$	58,070
EARNINGS PER SHARE – BASIC	$	0.86			$	0.77			$	0.63			$	1.99			$	1.84
EARNINGS PER SHARE – DILUTED	$	0.86			$	0.76			$	0.63			$	1.99			$	1.84
WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING		36,365,612				36,373,749				31,481,135				35,318,125				31,525,247

HBT Financial, Inc. Unaudited Consolidated Financial Summary Consolidated Balance Sheets
(dollars in thousands)	September 30, 2026				June 30, 2026				September 30, 2025
ASSETS
Cash and due from banks	$	28,860			$	28,634			$	21,767
Interest-bearing deposits with banks		97,400				103,616				133,366
Cash and cash equivalents		126,260				132,250				155,133
Interest-bearing time deposits with banks		—				245				—
Debt securities available-for-sale, at fair value		1,065,551				1,085,908				793,730
Debt securities held-to-maturity		417,491				443,042				466,565
Equity securities with readily determinable fair value		3,475				3,546				3,279
Equity securities with no readily determinable fair value		6,671				6,438				2,609
Restricted stock, at cost		6,000				6,000				4,979
Loans held for sale		2,980				3,857				1,432
Loans, before allowance for credit losses		4,782,743				4,752,418				3,400,029
Allowance for credit losses		(60,475	)			(60,564	)			(41,900	)
Loans, net of allowance for credit losses		4,722,268				4,691,854				3,358,129
Bank owned life insurance		38,112				37,883				24,489
Bank premises and equipment, net		91,606				91,418				69,965
Bank premises held for sale		276				337				—
Foreclosed assets		656				766				1,007
Goodwill		81,949				81,949				59,820
Intangible assets, net		41,403				42,858				15,760
Mortgage servicing rights, at fair value		20,799				19,339				17,254
Investments in unconsolidated subsidiaries		1,614				1,614				1,614
Accrued interest receivable		39,427				35,082				23,575
Other assets		52,789				43,260				35,687
Total assets	$	6,719,327			$	6,727,646			$	5,035,027
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities
Deposits:
Noninterest-bearing	$	1,303,942			$	1,313,650			$	1,034,181
Interest-bearing		4,448,490				4,444,336				3,313,006
Total deposits		5,752,432				5,757,986				4,347,187
Federal Home Loan Bank advances		12,210				12,363				7,271
Subordinated notes		84,051				84,026				—
Junior subordinated debentures issued to capital trusts		52,953				52,939				52,894
Other liabilities		63,590				55,599				28,546
Total liabilities		5,965,236				5,962,913				4,435,898
Stockholders’ Equity
Common stock		385				385				329
Surplus		447,557				447,030				297,992
Retained earnings		412,781				390,528				354,864
Accumulated other comprehensive income (loss)		(62,949	)			(29,527	)			(27,119	)
Treasury stock at cost		(43,683	)			(43,683	)			(26,937	)
Total stockholders’ equity		754,091				764,733				599,129
Total liabilities and stockholders’ equity	$	6,719,327			$	6,727,646			$	5,035,027
SHARES OF COMMON STOCK OUTSTANDING		36,365,612				36,365,612				31,455,803

HBT Financial, Inc. Unaudited Consolidated Financial Summary
(dollars in thousands)	September 30, 2026				June 30, 2026				September 30, 2025
LOANS
Commercial and industrial	$	509,973			$	525,190			$	395,859
Commercial real estate – owner occupied		515,800				507,163				312,192
Commercial real estate – non-owner occupied		1,136,065				1,128,594				931,723
Construction and land development		476,352				429,793				269,924
Multi-family		648,969				666,586				514,801
One-to-four family residential		583,266				579,612				443,215
Agricultural and farmland		595,485				593,984				280,309
Municipal, consumer, and other		316,833				321,496				252,006
Total loans	$	4,782,743			$	4,752,418			$	3,400,029

(dollars in thousands)	September 30, 2026				June 30, 2026				September 30, 2025
DEPOSITS
Noninterest-bearing deposits	$	1,303,942			$	1,313,650			$	1,034,181
Interest-bearing deposits:
Interest-bearing demand		1,323,535				1,351,994				1,102,815
Money market		1,071,278				1,012,207				883,327
Savings		829,297				853,993				562,149
Time		1,224,380				1,226,142				764,715
Total interest-bearing deposits		4,448,490				4,444,336				3,313,006
Total deposits	$	5,752,432			$	5,757,986			$	4,347,187

HBT Financial, Inc. Unaudited Consolidated Financial Summary
	Three Months Ended
	September 30, 2026										June 30, 2026										September 30, 2025
(dollars in thousands)	Average Balance				Interest			Yield/Cost *			Average Balance				Interest			Yield/Cost *			Average Balance				Interest			Yield/Cost *
ASSETS
Loans	$	4,771,700			$	77,395		6.43	%		$	4,731,275			$	75,207		6.38	%		$	3,379,637			$	54,063		6.35	%
Debt securities		1,522,439				12,404		3.23				1,517,731				12,168		3.22				1,265,683				8,779		2.75
Deposits with banks		106,879				735		2.73				138,675				1,024		2.96				142,659				1,350		3.75
Other		17,807				128		2.88				17,455				184		4.20				12,540				144		4.51
Total interest-earning assets		6,418,825			$	90,662		5.60	%			6,405,136			$	88,583		5.55	%			4,800,519			$	64,336		5.32	%
Allowance for credit losses		(60,865	)									(60,590	)									(41,711	)
Noninterest-earning assets		381,651										389,370										268,353
Total assets	$	6,739,611									$	6,733,916									$	5,027,161
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities
Interest-bearing deposits:
Interest-bearing demand	$	1,358,462			$	2,386		0.70	%		$	1,359,038			$	2,238		0.66	%		$	1,113,391			$	1,676		0.60	%
Money market		1,018,285				5,296		2.06				943,871				4,572		1.94				833,812				4,638		2.21
Savings		841,588				1,212		0.57				864,584				1,209		0.56				568,001				399		0.28
Time		1,222,696				9,228		2.99				1,247,241				9,234		2.97				771,360				6,282		3.23
Total interest-bearing deposits		4,441,031				18,122		1.62				4,414,734				17,253		1.57				3,286,564				12,995		1.57
Securities sold under agreements to repurchase		—				—		—				2,492				14		2.34				6				—		—
Borrowings		19,701				126		2.53				24,721				170		2.76				7,256				31		1.68
Subordinated notes		84,038				1,233		5.82				84,013				1,245		5.94				32,714				387		4.69
Junior subordinated debentures issued to capital trusts		52,946				860		6.45				52,930				845		6.40				52,887				937		7.04
Total interest-bearing liabilities		4,597,716			$	20,341		1.76	%			4,578,890			$	19,527		1.71	%			3,379,427			$	14,350		1.68	%
Noninterest-bearing deposits		1,314,588										1,336,123										1,028,608
Noninterest-bearing liabilities		57,071										60,660										30,050
Total liabilities		5,969,375										5,975,673										4,438,085
Stockholders’ Equity		770,236										758,243										589,076
Total liabilities and stockholders’ equity	$	6,739,611									$	6,733,916									$	5,027,161
Net interest income/Net interest margin(1)					$	70,321		4.35	%						$	69,056		4.32	%						$	49,986		4.13	%
Tax-equivalent adjustment(2)						869		0.05								851		0.06								552		0.05
Net interest income (tax-equivalent basis)/ Net interest margin (tax-equivalent basis)(2) (3)					$	71,190		4.40	%						$	69,907		4.38	%						$	50,538		4.18	%
Net interest rate spread(4)								3.84	%									3.84	%									3.64	%
Net interest-earning assets(5)	$	1,821,109									$	1,826,246									$	1,421,092
Ratio of interest-earning assets to interest-bearing liabilities		1.40										1.40										1.42
Cost of total deposits								1.25	%									1.20	%									1.19	%
Cost of funds								1.36										1.32										1.29

____________________________________

*  Annualized measure.

(1)   Net interest margin represents net interest income divided by average total interest-earning assets.
(2)   On a tax-equivalent basis assuming a federal income tax rate of 21% and a state income tax rate of 9.5%.
(3)   See “Reconciliation of Non-GAAP Financial Measures” below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.
(4)   Net interest rate spread represents the difference between the yield on average interest-earning assets and the cost of average interest-bearing liabilities.
(5)   Net interest-earning assets represents total interest-earning assets less total interest-bearing liabilities.

HBT Financial, Inc. Unaudited Consolidated Financial Summary
	Nine Months Ended
	September 30, 2026										September 30, 2025
(dollars in thousands)	Average Balance				Interest			Yield/Cost *			Average Balance				Interest			Yield/Cost *
ASSETS
Loans	$	4,467,683			$	212,800		6.37	%		$	3,419,077			$	162,971		6.37	%
Debt securities		1,472,552				34,774		3.16				1,229,388				24,075		2.62
Deposits with banks		136,230				3,035		2.98				141,216				3,959		3.75
Other		16,562				475		3.84				12,579				388		4.12
Total interest-earning assets		6,093,027			$	251,084		5.51	%			4,802,260			$	191,393		5.33	%
Allowance for credit losses		(56,651	)									(41,962	)
Noninterest-earning assets		362,291										271,193
Total assets	$	6,398,667									$	5,031,491
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities
Interest-bearing deposits:
Interest-bearing demand	$	1,314,320			$	6,555		0.67	%		$	1,119,902			$	4,698		0.56	%
Money market		956,682				14,316		2.00				818,453				13,498		2.20
Savings		793,296				3,125		0.53				568,891				1,143		0.27
Time		1,137,688				25,488		3.00				778,618				19,430		3.34
Total interest-bearing deposits		4,201,986				49,484		1.57				3,285,864				38,769		1.58
Securities sold under agreements to repurchase		1,787				30		2.27				3,361				22		0.89
Borrowings		24,403				505		2.77				9,103				170		2.49
Subordinated notes		62,846				2,756		5.86				37,261				1,326		4.76
Junior subordinated debentures issued to capital trusts		52,931				2,545		6.43				52,871				2,754		6.97
Total interest-bearing liabilities		4,343,953			$	55,320		1.70	%			3,388,460			$	43,041		1.70	%
Noninterest-bearing deposits		1,267,702										1,039,564
Noninterest-bearing liabilities		53,632										31,242
Total liabilities		5,665,287										4,459,266
Stockholders’ Equity		733,380										572,225
Total liabilities and stockholders’ equity	$	6,398,667										5,031,491
Net interest income/Net interest margin(1)					$	195,764		4.30	%						$	148,352		4.13	%
Tax-equivalent adjustment(2)						2,369		0.05								1,645		0.05
Net interest income (tax-equivalent basis)/ Net interest margin (tax-equivalent basis)(2) (3)					$	198,133		4.35	%						$	149,997		4.18	%
Net interest rate spread(4)								3.81	%									3.63	%
Net interest-earning assets(5)	$	1,749,074									$	1,413,800
Ratio of interest-earning assets to interest-bearing liabilities		1.40										1.42
Cost of total deposits								1.21	%									1.20	%
Cost of funds								1.32										1.30

____________________________________
(1)   Net interest margin represents net interest income divided by average total interest-earning assets.
(2)   On a tax-equivalent basis assuming a federal income tax rate of 21% and a state income tax rate of 9.5%.
(3)   See “Reconciliation of Non-GAAP Financial Measures” below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.
(4)   Net interest rate spread represents the difference between the yield on average interest-earning assets and the cost of average interest-bearing liabilities.
(5)   Net interest-earning assets represents total interest-earning assets less total interest-bearing liabilities.

HBT Financial, Inc. Unaudited Consolidated Financial Summary
(dollars in thousands)	September 30, 2026				June 30, 2026				September 30, 2025
NONPERFORMING ASSETS
Nonaccrual	$	10,098			$	9,083			$	7,637
Past due 90 days or more, still accruing		—				6				5
Total nonperforming loans		10,098				9,089				7,642
Foreclosed assets		656				766				1,007
Total nonperforming assets	$	10,754			$	9,855			$	8,649
Nonperforming loans that are wholly or partially guaranteed by the U.S. Government	$	2,350			$	2,405			$	1,760
Allowance for credit losses	$	60,475			$	60,564			$	41,900
Loans, before allowance for credit losses		4,782,743				4,752,418				3,400,029
CREDIT QUALITY RATIOS
Allowance for credit losses to loans, before allowance for credit losses		1.26	%			1.27	%			1.23	%
Allowance for credit losses to nonaccrual loans		598.88				666.78				548.64
Allowance for credit losses to nonperforming loans		598.88				666.34				548.29
Nonaccrual loans to loans, before allowance for credit losses		0.21				0.19				0.22
Nonperforming loans to loans, before allowance for credit losses		0.21				0.19				0.22
Nonperforming assets to total assets		0.16				0.15				0.17
Nonperforming assets to loans, before allowance for credit losses, and foreclosed assets		0.22				0.21				0.25

		Three Months Ended												Nine Months Ended September 30,
(dollars in thousands)		September 30, 2026				June 30, 2026				September 30, 2025					2026				2025
ALLOWANCE FOR CREDIT LOSSES
Beginning balance		$	60,564			$	60,474			$	41,659			$	41,690			$	42,044
Allowance established in acquisition			—				—				—				19,957				—
Provision for credit losses			(593	)			(10	)			375				(1,018	)			1,466
Charge-offs			(552	)			(314	)			(723	)			(1,867	)			(2,640	)
Recoveries			1,056				414				589				1,713				1,030
Ending balance		$	60,475			$	60,564			$	41,900			$	60,475			$	41,900
Net charge-offs (recoveries)		$	(504	)		$	(100	)		$	134			$	154			$	1,610
Average loans			4,771,700				4,731,275				3,379,637				4,467,683				3,419,077
Net charge-offs (recoveries) to average loans *			(0.04)	%			(0.01)	%			0.02	%			—	%			0.06	%

____________________________________

*  Annualized measure.

		Three Months Ended											Nine Months Ended September 30,
(dollars in thousands)		September 30, 2026				June 30, 2026				September 30, 2025				2026				2025
PROVISION FOR CREDIT LOSSES
Loans		$	(593	)		$	(10	)		$	375		$	(1,018	)		$	1,466
Unfunded lending-related commitments			32				686				221			977				232
Total provision for credit losses		$	(561	)		$	676			$	596		$	(41	)		$	1,698

Reconciliation of Non-GAAP Financial Measures – Adjusted Net Income and Adjusted Return on Average Assets
		Three Months Ended												Nine Months Ended September 30,
(dollars in thousands)		September 30, 2026				June 30, 2026				September 30, 2025					2026				2025
Net income		$	31,392			$	27,844			$	19,765			$	70,436			$	58,070
Less: adjustments
Acquisition expenses			(1,005	)			(257	)			—				(16,928	)			—
Net earnings (losses) on closed or sold operations			—				47				—				51				—
Loss on extinguishment of debt			—				—				(391	)			—				(391	)
Gains (losses) on closed branch premises			(61	)			—				(7	)			(271	)			2
Realized gains (losses) on sales of securities			(184	)			—				(49	)			(184	)			(49	)
Mortgage servicing rights fair value adjustment			1,460				(751	)			(514	)			906				(1,573	)
Total adjustments			210				(961	)			(961	)			(16,426	)			(2,011	)
Tax effect of adjustments(1)			(229	)			270				274				4,306				573
Total adjustments after tax effect			(19	)			(691	)			(687	)			(12,120	)			(1,438	)
Adjusted net income		$	31,411			$	28,535			$	20,452			$	82,556			$	59,508
Average assets		$	6,739,611			$	6,733,916			$	5,027,161			$	6,398,667			$	5,031,491
Return on average assets *			1.85	%			1.66	%			1.56	%			1.47	%			1.54	%
Adjusted return on average assets *			1.85				1.70				1.61				1.73				1.58

____________________________________

*  Annualized measure.

(1)   Assumes a federal income tax rate of 21% and a state income tax rate of 9.5%, and excludes non-deductible acquisition expenses.

Reconciliation of Non-GAAP Financial Measures – Adjusted Earnings Per Share — Basic and Diluted
		Three Months Ended									Nine Months Ended September 30,
(dollars in thousands, except per share amounts)		September 30, 2026			June 30, 2026			September 30, 2025				2026			2025
Numerator:
Net income		$	31,392		$	27,844		$	19,765		$	70,436		$	58,070
Adjusted net income		$	31,411		$	28,535		$	20,452		$	82,556		$	59,508
Denominator:
Weighted average common shares outstanding			36,365,612			36,373,749			31,481,135			35,318,125			31,525,247
Dilutive effect of outstanding restricted stock units			123,811			92,939			106,800			112,293			103,682
Weighted average common shares outstanding, including all dilutive potential shares			36,489,423			36,466,688			31,587,935			35,430,418			31,628,929
Earnings per share – basic		$	0.86		$	0.77		$	0.63		$	1.99		$	1.84
Earnings per share – diluted		$	0.86		$	0.76		$	0.63		$	1.99		$	1.84
Adjusted earnings per share – basic		$	0.86		$	0.78		$	0.65		$	2.34		$	1.89
Adjusted earnings per share – diluted		$	0.86		$	0.78		$	0.65		$	2.33		$	1.88

Reconciliation of Non-GAAP Financial Measures – Pre-Provision Net Revenue, Pre-Provision Net Revenue Less Net Charge-offs (Recoveries), Adjusted Pre-Provision Net Revenue, and Adjusted Pre-Provision Net Revenue Less Net Charge-offs (Recoveries)
		Three Months Ended												Nine Months Ended September 30,
(dollars in thousands)		September 30, 2026				June 30, 2026				September 30, 2025					2026				2025
Net interest income		$	70,321			$	69,056			$	49,986			$	195,764			$	148,352
Noninterest income			14,237				11,841				9,849				37,022				28,295
Noninterest expense			(42,663	)			(42,446	)			(32,508	)			(137,546	)			(96,357	)
Pre-provision net revenue			41,895				38,451				27,327				95,240				80,290
Less: adjustments
Acquisition expenses			(1,005	)			(257	)			—				(16,928	)			—
Net earnings (losses) on closed or sold operations			—				47				—				51				—
Loss on extinguishment of debt			—				—				(391	)			—				(391	)
Gains (losses) on closed branch premises			(61	)			—				(7	)			(271	)			2
Realized gains (losses) on sales of securities			(184	)			—				(49	)			(184	)			(49	)
Mortgage servicing rights fair value adjustment			1,460				(751	)			(514	)			906				(1,573	)
Total adjustments			210				(961	)			(961	)			(16,426	)			(2,011	)
Adjusted pre-provision net revenue		$	41,685			$	39,412			$	28,288			$	111,666			$	82,301
Pre-provision net revenue		$	41,895			$	38,451			$	27,327			$	95,240			$	80,290
Less: net charge-offs (recoveries)			(504	)			(100	)			134				154				1,610
Pre-provision net revenue less net charge-offs (recoveries)		$	42,399			$	38,551			$	27,193			$	95,086			$	78,680
Adjusted pre-provision net revenue		$	41,685			$	39,412			$	28,288			$	111,666			$	82,301
Less: net charge-offs (recoveries)			(504	)			(100	)			134				154				1,610
Adjusted pre-provision net revenue less net charge-offs (recoveries)		$	42,189			$	39,512			$	28,154			$	111,512			$	80,691

Reconciliation of Non-GAAP Financial Measures – Net Interest Income (Tax-equivalent Basis) and Net Interest Margin (Tax-equivalent Basis)
		Three Months Ended												Nine Months Ended September 30,
(dollars in thousands)		September 30, 2026				June 30, 2026				September 30, 2025					2026				2025
Net interest income (tax-equivalent basis)
Net interest income		$	70,321			$	69,056			$	49,986			$	195,764			$	148,352
Tax-equivalent adjustment(1)			869				851				552				2,369				1,645
Net interest income (tax-equivalent basis)(1)		$	71,190			$	69,907			$	50,538			$	198,133			$	149,997
Net interest margin (tax-equivalent basis)
Net interest margin *			4.35	%			4.32	%			4.13	%			4.30	%			4.13	%
Tax-equivalent adjustment *(1)			0.05				0.06				0.05				0.05				0.05
Net interest margin (tax-equivalent basis) *(1)			4.40	%			4.38	%			4.18	%			4.35	%			4.18	%
Average interest-earning assets		$	6,418,825			$	6,405,136			$	4,800,519			$	6,093,027			$	4,802,260

____________________________________

*  Annualized measure.

(1)   On a tax-equivalent basis assuming a federal income tax rate of 21% and a state income tax rate of 9.5%.

Reconciliation of Non-GAAP Financial Measures – Efficiency Ratio (Tax-equivalent Basis) and Adjusted Efficiency Ratio (Tax-equivalent Basis)
		Three Months Ended												Nine Months Ended September 30,
(dollars in thousands)		September 30, 2026				June 30, 2026				September 30, 2025					2026				2025
Total noninterest expense		$	42,663			$	42,446			$	32,508			$	137,546			$	96,357
Less: amortization of intangible assets			1,455				1,455				694				3,797				2,083
Noninterest expense excluding amortization of intangible assets			41,208				40,991				31,814				133,749				94,274
Less: adjustments to noninterest expense
Acquisition expenses			1,005				257				—				16,928				—
Expenses from closed or sold operations			—				124				—				273				—
Loss on extinguishment of debt			—				—				391				—				391
Total adjustments to noninterest expense			1,005				381				391				17,201				391
Adjusted noninterest expense		$	40,203			$	40,610			$	31,423			$	116,548			$	93,883
Net interest income		$	70,321			$	69,056			$	49,986			$	195,764			$	148,352
Total noninterest income			14,237				11,841				9,849				37,022				28,295
Operating revenue			84,558				80,897				59,835				232,786				176,647
Tax-equivalent adjustment(1)			869				851				552				2,369				1,645
Operating revenue (tax-equivalent basis)(1)			85,427				81,748				60,387				235,155				178,292
Less: adjustments to noninterest income
Revenue from closed or sold operations			—				171				—				324				—
Gains (losses) on closed branch premises			(61	)			—				(7	)			(271	)			2
Realized gains (losses) on sales of securities			(184	)			—				(49	)			(184	)			(49	)
Mortgage servicing rights fair value adjustment			1,460				(751	)			(514	)			906				(1,573	)
Total adjustments to noninterest income			1,215				(580	)			(570	)			775				(1,620	)
Adjusted operating revenue (tax-equivalent basis)(1)		$	84,212			$	82,328			$	60,957			$	234,380			$	179,912
Efficiency ratio			48.73	%			50.67	%			53.17	%			57.46	%			53.37	%
Efficiency ratio (tax-equivalent basis)(1)			48.24				50.14				52.68				56.88				52.88
Adjusted efficiency ratio (tax-equivalent basis)(1)			47.74				49.33				51.55				49.73				52.18

____________________________________
(1)   On a tax-equivalent basis assuming a federal income tax rate of 21% and a state income tax rate of 9.5%.

Reconciliation of Non-GAAP Financial Measures – Ratio of Tangible Common Equity to Tangible Assets and Tangible Book Value Per Share
(dollars in thousands, except per share data)		September 30, 2026				June 30, 2026				September 30, 2025
Tangible Common Equity
Total stockholders’ equity		$	754,091			$	764,733			$	599,129
Less: Goodwill			81,949				81,949				59,820
Less: Intangible assets			41,403				42,858				15,760
Tangible common equity		$	630,739			$	639,926			$	523,549
Tangible Assets
Total assets		$	6,719,327			$	6,727,646			$	5,035,027
Less: Goodwill			81,949				81,949				59,820
Less: Intangible assets			41,403				42,858				15,760
Tangible assets		$	6,595,975			$	6,602,839			$	4,959,447
Total stockholders’ equity to total assets			11.22	%			11.37	%			11.90	%
Tangible common equity to tangible assets			9.56				9.69				10.56
Shares of common stock outstanding			36,365,612				36,365,612				31,455,803
Book value per share		$	20.74			$	21.03			$	19.05
Tangible book value per share			17.34				17.60				16.64

Reconciliation of Non-GAAP Financial Measures – Return on Average Tangible Common Equity, Adjusted Return on Average Stockholders’ Equity and Adjusted Return on Average Tangible Common Equity
		Three Months Ended												Nine Months Ended September 30,
(dollars in thousands)		September 30, 2026				June 30, 2026				September 30, 2025					2026				2025
Average Tangible Common Equity
Total stockholders’ equity		$	770,236			$	758,243			$	589,076			$	733,380			$	572,225
Less: Goodwill			81,949				83,487				59,820				77,855				59,820
Less: Intangible assets			42,109				43,604				16,095				37,094				16,781
Average tangible common equity		$	646,178			$	631,152			$	513,161			$	618,431			$	495,624
Net income		$	31,392			$	27,844			$	19,765			$	70,436			$	58,070
Adjusted net income			31,411				28,535				20,452				82,556				59,508
Return on average stockholders’ equity *			16.17	%			14.73	%			13.31	%			12.84	%			13.57	%
Return on average tangible common equity *			19.27				17.69				15.28				15.23				15.66
Adjusted return on average stockholders’ equity *			16.18	%			15.09	%			13.77	%			15.05	%			13.90	%
Adjusted return on average tangible common equity *			19.29				18.13				15.81				17.85				16.05

____________________________________

*  Annualized measure.